Knee osteoarthritis (OA) is a common joint disorder associated with pain, disability, and joint damage. There is a large unmet need for safe and efficacious treatments for treatment of symptoms and structural modification. Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate Wnt and inflammatory pathways, is in development as a potential treatment for knee OA.

The primary objective of this trial was to assess the safety and tolerability of repeated 6-month dosing of LOR in a 104-week trial (OA-06, NCT03727022). This trial also sought to characterize juxta-articular bone health using quantitative computed tomography (QCT) and regional bone health via dual energy x-ray absorptiometry (DXA).

Participants with ACR-defined clinical and radiographic OA, aged 40-80, and Kellgren-Lawrence (KL) grades 2-3 were randomized 1:1 to receive IA injections of 2 mL 0.07 mg LOR or vehicle PBO at baseline, 24 weeks, 52 weeks, and 72 weeks (4 injections total). The trial was conducted in two 52-week phases, part A (baseline - week 52) and part B (week 53 - week 104), with A completers invited to B. General safety was assessed by physical examinations, clinical laboratory tests, and collection of adverse events (AEs) and serious AEs (SAEs).

Bone safety assessments included target and non-target knee QCT (standardized by calibration phantom), bone and cartilage biomarkers, and DXA of hip and spine. Exploratory efficacy was assessed by patient-reported outcomes (PROs). For bone imaging endpoints, change from baseline was estimated using baseline-adjusted ANCOVA.

Participants with ACR-defined clinical and radiographic OA, aged 40-80, and Kellgren-Lawrence (KL) grades 2-3 were randomized 1:1 to receive IA injections of 2 mL 0.07 mg LOR or vehicle PBO at baseline, 24 weeks, 52 weeks, and 72 weeks (4 injections total). The trial was conducted in two 52-week phases, part A (baseline - week 52) and part B (week 53 - week 104), with A completers invited to B. General safety was assessed by physical examinations, clinical laboratory tests, and collection of adverse events (AEs) and serious AEs (SAEs).

There were no clinical signals for change in bone health, with no fractures, accelerated OA, or osteoporosis observed in LOR or PBO. Observed target knee BMD values as assessed by QCT were similar between LOR and PBO (Figure 1).

There were no effects of repeated injection on rates of change in BMDs; the change from baseline in BMD at Week 104 was -7.08 (12.34) mg/cm² in LOR and -2.95 (8.65) mg/cm² in PBO, (estimated difference -4.05 [95% CI -11.21, 3.11], not significant).

There were no significant differences between LOR and PBO in females and age [65-80] (those with potentially higher risk of decreased bone density) in target knee nor total hip or spine BMD.

There were no meaningful differences in PRO changes between LOR and PBO groups.

A trial conduct limitation was the small number of QCT-enabled sites in the US. Potential confounding factors included baseline imbalances in sex (PBO 68.0% vs. LOR 51.0% female), KL grade (PBO 62.0% vs LOR 42.1% KL 2), and site randomization.

Conclusions

• The incidence of AEs was similar between treatment groups and not affected by repeated injections of LOR.

• Multiple injections of LOR over 2 years did not appear adversely affect bone health locally around the knee or regionally at spine or hip.